CMB Stock News Of The Day 📰📰🗞️🗞️📈📉

Moderna Stock Climbs as RFK Jr. Panel Issues Softer-Than-Expected Covid Vaccine Guidance🚨🚨🚨

Moderna shares climbed more than 6% on Monday to $26.78 after a federal vaccine advisory panel offered a scaled-back Covid vaccine recommendation that proved less restrictive than many investors had feared.

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted Friday to end universal guidance that all Americans receive a Covid shot. Instead, the panel now suggests people consult their doctors before getting vaccinated. Crucially, however, the committee stopped short of requiring prescriptions for the vaccine—an outcome that would have been a far bigger blow to Moderna.

Moderna, which was fast-tracked by the Trump administration to develop its Covid vaccine in 2020, still relies on the shot for nearly all of its revenue. While the updated guidance may reduce the number of people receiving doses, it avoids the harsher restrictions some had braced for.

The vote took place under unusual circumstances. ACIP was reconstituted by Health and Human Services Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic. According to NPR, the meeting was plagued by technical glitches, disputes among members, and heated debate. A separate decision on whether to delay infants’ hepatitis B shots was also postponed.

Elsewhere in healthcare stocks, Tylenol-maker Kenvue dropped nearly 7% after The Washington Post reported that HHS may move to connect the widely used pain reliever to autism risks.